1187316-83-1

Basic information

• Product Name: tetra-tert-butyl [({5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl)}tetrakis(azanediyl))tetrakis(ethane-2,1-diyl)]tetracarbamate
• Synonyms: tetra-tert-butyl [({5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl)}tetrakis(azanediyl))tetrakis(ethane-2,1-diyl)]tetracarbamate
• CAS NO: 1187316-83-1
• Molecular Weight: 1754.51
• Mol File: 1187316-83-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tetra-tert-butyl [({5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl)}tetrakis(azanediyl))tetrakis(ethane-2,1-diyl)]tetracarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tetra-tert-butyl [({5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl)}tetrakis(azanediyl))tetrakis(ethane-2,1-diyl)]tetracarbamate(1187316-83-1)
• EPA Substance Registry System: tetra-tert-butyl [({5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl)}tetrakis(azanediyl))tetrakis(ethane-2,1-diyl)]tetracarbamate(1187316-83-1)

Safety Data

• Hazardous Substances Data: 1187316-83-1(Hazardous Substances Data)

Upstream product

• 57260-73-8 N-BOC-1,2-diaminoethane 
• 79944-44-8 5,5′-[malonylbis(azanediyl)]bis(2,4,6-triiodoisophthaloyl dichloride) 
• 37441-29-5 5-amino-2,4,6-triiodoisophthalic acid dichloride 
• 35453-19-1 2,4,6-triiodo-5-aminoisophthalic acid 

Relevant articles and documents

Synthesis and Preclinical Characterization of a Cationic Iodinated Imaging Contrast Agent (CA4+) and Its Use for Quantitative Computed Tomography of Ex Vivo Human Hip Cartilage

Contrast agents that go beyond qualitative visualization and enable quantitative assessments of functional tissue performance represent the next generation of clinically useful imaging tools. An optimized and efficient large-scale synthesis of a cationic iodinated contrast agent (CA4+) is described for imaging articular cartilage. Contrast-enhanced CT (CECT) using CA4+ reveals significantly greater agent uptake of CA4+ in articular cartilage compared to that of similar anionic or nonionic agents, and CA4+ uptake follows Donnan equilibrium theory. The CA4+ CECT attenuation obtained from imaging ex vivo human hip cartilage correlates with the glycosaminoglycan content, equilibrium modulus, and coefficient of friction, which are key indicators of cartilage functional performance and osteoarthritis stage. Finally, preliminary toxicity studies in a rat model show no adverse events, and a pharmacokinetics study documents a peak plasma concentration 30 min after dosing, with the agent no longer present in vivo at 96 h via excretion in the urine.